The pharmacokinetics of mavacoxib, a long-acting COX-2 inhibitor, in young adult laboratory dogs

Journal of Veterinary Pharmacology and Therapeutics

Volumn 33, Issue 5, 2010, Pages 461-470

  Cox, S R ^a   Lesman, S P ^a   Boucher, J F ^a   Krautmann, M J ^a   Hummel, B D ^a   Savides, M ^c   Marsh, S ^a   Fielder, A ^a   Stegemann, M R ^b  

^a PFIZER INC   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^c Ricerca Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; LONG ACTING DRUG; MAVACOXIB; PLASMA PROTEIN; TROCOXIL; UNCLASSIFIED DRUG; VETERINARY DRUG;

ADULT; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; DIGESTIVE SYSTEM PERFORATION; DOSE RESPONSE; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG SAFETY; EX VIVO STUDY; EXPERIMENTAL DOG; FEMALE; FOOD; FOOD DRUG INTERACTION; HUMAN; IN VITRO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; TIME TO MAXIMUM PLASMA CONCENTRATION; TOXICOKINETICS;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AREA UNDER CURVE; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HALF-LIFE; MALE; PYRAZOLES; STEREOISOMERISM;

CANIS FAMILIARIS;

EID: 77956624392     PISSN: 01407783     EISSN: 13652885     Source Type: Journal    
DOI: 10.1111/j.1365-2885.2010.01165.x     Document Type: Article

References (23)

1. Brandt, K.D., Braunstein, E.M., Visco, D.M., O'Connor, B., Heck, D. Albrecht, M. (1991) Anterior (Cranial) cruciate ligament transection in the dog: a bona fide model of osteoarthritis, not merely of cartilage injury and repair. Journal of Rheumatology, 18, 436 446.
2. Cox, S.R., Liao, S.H.T., Payne-Johnson, M., Zielinski, R.J. Stegemann, M.R. (2010) Population pharmacokinetics of mavacoxib, a long-acting COX-2 inhibitor, in osteoarthritic dogs. Journal of Veterinary Pharmacology and Therapeutics (in press).
3. Davies, B. Morris, T. (1993) Physiological parameters in laboratory animals and humans. Pharmaceutical Research, 10, 1093 1095.
4. EMEA (2006) European Medicines Agency, Zubrin - European Public Assessment Report. Available at: http://www.ema.europa.eu/vetdocs/PDFs/EPAR/ zubrin/V-057-en6.pdf. Accessed 19 January 2010.
5. EMEA (2008a) European Medicines Agency, Onsior - European Public Assessment Report. http://www.ema.europa.eu/vetdocs/vets/Epar/onsior/onsior.htm. Accessed 19 January 2010.
6. EMEA (2008b) European Medicines Agency, Trocoxil - European Public Assessment Report. Available at: http://www.ema.europa.eu/vetdocs/PDFs/EPAR/ trocoxil/V-132-en7.pdf. Accessed 19 January 2010.
7. Fiorentino, P.M., Tallents, R.H., Miller, J.N.H., Brouxhon, S.M., O'Banion, M.K., Puzas, J.E. Kyrkanides, S. (2008) Spinal interleukin-1 beta in a mouse model of arthritis and joint pain. Arthritis and Rheumatism, 58, 3100 3109.
8. Hauge, E.M., Melsen, F. Hansen, E. (1995) Protective effects of Naproxen on juxta-articular bone structure in canine carrageenan-induced juvenile arthritis. European Journal of Experimental Musculoskelatal Research, 4, 125 132.
9. Hummel, B.D., Locuson, C.P., Benner, M.J., Cox, T.D., Cox, S.R. Stegemann, M.R. (2010) Manuscript in preparation.
10. Johnston, S.A. (1997) Osteoarthritis: joint anatomy, physiology, and pathobiology. Veterinary Clinics of North America. Small Animal Practice, 27, 699 723.
11. Krautmann, M.J., Savides, M.C., Boucher, J.F., Cox, S.R. Stegemann, M.R. (2010) Safety of mavacoxib administered orally in dogs. Manuscript in preparation.
12. Lees, P., Alexander-Bowman, S., Hummel, B., Kubiak, T., Michels, G., Krautmann, M., Cox, S., Toutain, P.L. Stegemann, M. (2009) Pharmacokinetics and pharmacodyanamics of mavacoxib in the dog. Presented at the 11th International Congress of The European Association for Veterinary Pharmacology and Toxicology, Leipzig, Germany, 12-16 July 2009. Journal of Veterinary Pharmacology and Therapeutics, 32 (Suppl. 1 105 106.
13. Li, J., DeMello, K.M., Cheng, H., Sakya, S.M., Bronk, B.S., Rafka, R.J., Jaynes, B.H., Ziegler, C.B., Kilroy, C., Mann, D.W., Nimz, E.L., Lynch, M.P., Haven, M.L., Kolosko, N.L., Minich, M.L., Li, C., Dutra, J.K., Rast, B., Crosson, R.M., Morton, B.J., Kirk, G.W., Callaghan, K.M., Koss, D.A., Shavnya, A., Lund, L.A., Seibel, S.B., Petras, C.F. Silvia, A. (2004) Discovery of a potent, selective and orally active canine COX-2 inhibitor, 2-(3-difluoromethyl- 5-phenyl-pyrazol-1-yl)-5-methanesulfonyl-pyridine. Bioorganic & Medicinal Chemistry Letters, 14, 95 98.
14. Novartis Animal Health (2007) Deramaxx Prescribing Information. Available at: http://www.deramaxx.com/content/ProductLabel.pdf. Accessed 19 January 2010.
15. OECD (1998) Organisation for Economic Co-operation and Development: Environment Directorate - OECD Principles of Good Laboratory Practice. OECD, Paris, France.
16. Paulson, S.K., Zhang, J.Y., Jessen, S.M., Lawal, Y., Liu, N.W., Dudkowski, C.M., Wang, Y.F., Chang, M., Yang, D., Findlay, J.W., Berge, M.A., Markos, C.S., Breau, A.P., Hribar, J.D. Yuan, J. (2000) Comparison of celecoxib metabolism and excretion in mouse, rabbit, dog, cynomolgus monkey and rhesus monkey. Xenobiotica, 30, 731 744.
17. Paulson, S.K., Vaughn, M.B., Jessen, S.M., Lawal, Y., Gresk, C.J., Yan, B., Maziasz, T.J., Cook, C.S. Karim, A. (2001) Pharmacokinetics of celecoxib after oral administration in dogs and humans: effect of food and site of absorption. Journal of Pharmacology and Experimental Therapeutics, 297, 638 645.
18. Payne-Johnson, M., Boucher, J.F. Stegemann, M.R. (2009) Efficacy and safety of mavacoxib in the treatment of pain and inflammation associated with degenerative joint disease in dogs presented as veterinary patients. Presented at the 11th International Congress of the European Association for Veterinary Pharmacology and Toxicology, Leipzig, Germany, 12-16 July 2009, Journal of Veterinary Pharmacology and Therapeutics, 32 (Suppl. 1 106 107
19. Pelletier, J.P., Lajeunesse, D., Jovanovic, D.V., Lascau-Coman, V., Jolicoeur, F.C., Hilal, G., Fernandes, J.C. Martel-Pelletier, J. (2000) Carprofen simultaneously reduces progression of morphological changes in cartilage and subchondral bone in experimental dog osteoarthritis. Journal of Rheumatology, 27, 2893 2902.
20. Penning, T.D., Talley, J.J., Bertenshaw, S.R., Carter, J.S., Collins, P.W., Docter, S., Graneto, M.J., Lee, L.F., Malecha, J.W., Miyashiro, J.M., Rogers, R.S., Rogier, D.J., Yu, S.S., Anderson, G.D., Burton, E.G., Cogburn, J.N., Gregory, S.A., Koboldt, C.M., Perkins, W.E., Seibert, K., Veenhuizen, A.W., Zhang, Y.Y. Isakson, P.C. (1997) Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib). Journal of Medicinal Chemistry, 40, 1347 1365.
21. Priymenko, N., Garnier, F., Ferre, J.P., Delatour, P. Toutain, P.L. (1998) Enantioselectivity of the enterohepatic recycling of Carprofen in the dog. Drug Metabolism and Disposition, 26, 170 176.
22. Sanderson, R.O., Beata, C., Flipo, R.M., Genevois, J.P., Macias, C., Vezzoni, A. Innes, J.F. (2009) Systematic review of the management of canine osteoarthritis. Veterinary Record, 164, 418 424.
23. VICH (2007) VICH Topic GL43: Guideline on Target Animal Safety for Pharmaceuticals. Available at: http://www.ema.europa.eu/pdfs/vet/vich/ 39338806en.pdf. Accessed 18 January 2010.